FOR IMMEDIATE RELEASE
EpiCypher Expands Global Distribution Network
Company responds to increased global demand for products and services.
Research Triangle Park, NC - 16 February 2016 - EpiCypher Inc. added five strategic distributors in 2015 responding to increased global demand for the Company’s products and services. A total of 16 companies now represent EpiCypher outside of the United States, including nine in Europe.
EpiCypher announced the following distributors after the significant training and support from EpiCypher to enable success in their local markets.
- MJS BioLynx, Inc; Brockville, Ontario, Canada (biolynx.ca)
- ABclonal Biotechnology Co., Ltd; Wuhan, Hubei, P.R.China (abclonal.com)
- Bioinborn Scientific, Inc; Wuhan City, China P.C. (bioinborn.com)
- Cistron Biolab, Kattupakkam, Chennai, India (cistronbiolab.com)
- KOMA BIOTECH, Seoul, South Korea (komabiotech.com)
“The addition of these highly reputable companies to the EpiCypher distributor portfolio will broaden our sales capacity in established international markets”, said Danielle Mahon, Director of Scientific Sales, EpiCypher. “The end-user will benefit from local customer service and expedited shipping of our products.”
FOR IMMEDIATE RELEASE
EpiCypher Announces Key Appointments to Bolster Sales and Product Development
Expansion of management team deepens scientific capability, client service and support.
Research Triangle Park, NC – 16 February 2016 – EpiCypher Inc., a global provider of epigenetics research products and services, today announced the appointment of two talented individuals to its management team in response to new R&D directives and an increased share of the epigenetics products market.
Danielle Mahon. Director, Scientific Sales
Ms. Mahon brings 21 years of successful sales experience to EpiCypher including the last 10 years in the life science arena managing capital equipment and consumable sales in pharmaceutical, biotechnology and academic settings. During this time Ms. Mahon worked for industry leaders including Eppendorf, Mettler Toledo and ThermoFisher Scientific. She has a strong track record with key account development and management. She holds a Bachelors of Science in Management from Rutgers University.
Michael-Christopher Keogh, Ph.D. Director, Markets and Application Development
Dr. Keogh earned his PhD in Molecular Immunology from Imperial College London and completed postdoctoral studies in the Thrombosis Research Institute (London) and with Dr. Steve Buratowski at Harvard Medical School. Prior to joining EpiCypher he was a Principal Investigator in the Department of Cell Biology at Albert Einstein College of Medicine. His work has focused on many key oncology research areas including cell-cycle regulation, DNA repair, epigenetics, gene expression and genetic networks.
“The addition of these highly talented and experienced individuals to the EpiCypher team deepens our capability to deliver innovative and practical solutions to our customer base. Danielle brings world-class success in delivering global customer success and distributor engagement. In her role, Danielle will develop and implement our commercial strategy,” said Sam C. Tetlow, CEO, EpiCypher. “Michael brings exceptional scientific experience with an outstanding publication track record. His external focus on application development will significantly benefit our customer base. In his role, Michael will bring forward EpiCypher’s deep scientific expertise in driving development and adoption of our innovative product portfolio”.
About EpiCypher - A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers worldwide. EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services.
For more information about EpiCypher, visit EpiCypher.com.
Sam Tetlow, CEO